Jacob Silverman

Mr. Jacob Silverman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JSJacob Silverman
Jacob Silverman
SSSayanthen Sathyakumar
Sayanthen Sathyakumar
HCHallie Coltin
Hallie Coltin
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
NJNada Jabado
Nada Jabado
SRSamuele Renzi
Samuele Renzi
Bevacizumab is often used off-label in pediatric neuro-oncology, and evidence for indications of bevacizumab use in pediatric neuro-oncology is often fragmented. Therefore, this review aims to provide an organized summary of efficacy across different types of tumors, highlight outcomes, and link findings to the underlying biology. Gaps in the literature were also identified to guide future research. We narratively synthesized various pediatric studies, and the following tumor categories were identified for discussion: low-grade glioma, high-grade glioma, diffuse intrinsic pontine glioma, schwannoma, medulloblastoma, radiation necrosis, and cerebral edema. Key outcomes considered included overall survival, event-free survival, progression-free survival, vision and/or hearing improvements, steroid use, quality of life, and toxicity. The greatest benefits were observed in cases such as recurrent medulloblastoma in combination with temozolomide and irinotecan, optic pathway glioma visual function, and diminished steroid use in radiation necrosis. Results were poorer in cases of newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. The medication was overall well tolerated, with adverse events like hypertension, proteinuria, and epistaxis often being manageable with surveillance. In consideration of the results, bevacizumab should be considered based on the tumor profile, and its outcome measured along functional endpoints, besides radiological evolution. Continued investigations into outcome measures, as well as combination with targeted treatments and optimizing therapy, will contribute to improving outcomes in this vulnerable population.

1 July 2025 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
JSJacob Silverman
Jacob Silverman
MMMelissa Mégalli
Melissa Mégalli
EGEmilie Giguère
Emilie Giguère
SESarah Elbaz
Sarah Elbaz
MLMelanie Letourneau
Melanie Letourneau
SRSamuele Renzi
Samuele Renzi
Background: Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome. Observations: We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis. Conclusions: This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.